Metas de control glucémico en pacientes con deterioro cognitivo

Diabetes mellitus represents one of the most frequent metabolic comorbidities among the geriatric population, affecting approximately 30% of older adults. Its clinical management poses a complex challenge, primarily driven by the co-occurrence of multiple chronic comorbid conditions that directly condition and limit individual self-care capacity. This multidimensional clinical complexity necessitates a timely understanding regarding how and when to re-evaluate and readjust the overall therapeutic regimen in accordance with the patient's evolving health needs, disease trajectory, and functional capacity1. The overall prevalence of cognitive impairment in individuals living with diabetes increases progressively with advancing chronological age, extended disease duration, and persistently elevated glycated hemoglobin (HbA1c) levels. Nevertheless, rigorous clinical evidence has demonstrated that severe manifestations of cognitive impairment can be delayed or effectively prevented through optimal management of associated cardiovascular and metabolic comorbidities, including systemic arterial hypertension, dyslipidemia, tobacco use, obesity, and poor glycemic control2. When conducting a thorough clinical evaluation of older adults diagnosed with diabetes, it is imperative to precisely determine the disease classification, duration of evolution, presence of vascular complications, patient self-management capability, socio-familial support network, overall treatment burden, fear of hypoglycemia, and potential financial barriers. Within this clinical context, preventing hypoglycemic events constitutes a priority therapeutic objective, given their severe adverse impact as major precipitating factors for accidental falls, acute cardiovascular events, and the exacerbation of underlying cognitive deterioration3. Furthermore, polypharmacy secondary to managing these associated comorbid conditions significantly amplifies these same clinical risks. Polypharmacy is independently associated with a heightened incidence of physical frailty, protein-calorie malnutrition, clinical depression, bone fractures, progressive functional decline, and overall mortality within this vulnerable patient demographic4. Consequently, it is fundamental to identify clinical and psychosocial warning signs in a timely manner whenever they compromise glycemic stability, thereby prompting a comprehensive re-evaluation of the overarching therapeutic strategy. In older adults, guaranteeing an optimal balance between treatment risks and clinical benefits consistently requires prioritizing patient safety through personalization, regimen simplification, or de-intensification of the pharmacological scheme, while establishing individualized and appropriately glycemic control targets.